AI-Coupled Plasmonic Sensor for Neurodegenerative Disease Detection: Cutting-Edge Technology

Without the ability to detect any developmental biomarkers, it becomes difficult to diagnose a vast majority of neurological disorders, such as dementia and Alzheimer’s. This is signaling the impetus of onset and spreading of diseases, both neural and non-neural. In this paper, we report the development of a nano-plasmonic infrared metasurface sensor-coupled immunoassay that uniquely uses absorption signatures to resolve the different structural species and identify alpha-synuclein. Up to this time, we have been able to predict the combination oligomeric and fibrillar protein mass combination to an accuracy that is achievable by a network of artificial neural networks, which has been considered infeasible. In this context, we can use the MEMS integrated sensor to collect the time-resolved wavelength fingerprints and multiplexing in the continuous sensor, which may be used in the presence of any complex bio-matrix that may allow for several pathologies associated indications. Our sensor could represent a feasible alternative that involves illness monitoring, new therapy assessment, and clinical evaluation of NDDs. Neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, are very challenging diseases with the need of early diagnosis and the complexity of the pathology involved. Structural protein biomarker detection has also been essential in diagnosing and observing diseases relative to NDDs. The paper presents the development and application of an artificial intelligence–coupled plasmonic infrared sensor designed for sensitive and specific detection of structural protein biomarkers associated with neurodegenerative diseases.